Palvella Therapeutics (PVLA) announced the publication of a systematic review in Clinical and Experimental Dermatology which synthesizes available published clinical evidence on off-label statin use for cutaneous application in porokeratosis. The systematic review supports the scientific rationale and clinical potential for developing Palvella’s Qtorin pitavastatin for the treatment of disseminated superficial actinic porokeratosis, DSAP, currently anticipated to enter Phase 2 development in the second half of 2026.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PVLA:
- 3 Best Stocks to Buy Today, 2/2/2026, According to Top Analysts
- Palvella Highlights QTORIN Rapamycin Progress in New Presentation
- 3 ‘Strong Buy’ Biotech Stocks to Buy Now, 1/29/2026, According to Top Analysts
- Physician Survey Underscores Undervalued Commercial Upside for QTORIN Topical Rapamycin, Supporting Buy on Palvella Therapeutics
- Palvella Therapeutics management to meet with Clear Street